A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.

MLA

Cohen, Jonathon B., et al. “A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma.” British Journal of Haematology, vol. 171, no. 4, Nov. 2015, pp. 539–46. EBSCOhost, https://doi.org/10.1111/bjh.13637.

APA

Cohen, J. B., Switchenko, J. M., Koff, J. L., Sinha, R., Kaufman, J. L., Khoury, H. J., Bumpers, N., Colbert, A., Hutchison, R. A., Nastoupil, L. J., Heffner, L. T., Langston, A. A., Lechowicz, M. J., Lonial, S., & Flowers, C. R. (2015). A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin’s lymphoma. British Journal of Haematology, 171(4), 539–546. https://doi.org/10.1111/bjh.13637

Chicago

Cohen, Jonathon B., Jeffrey M. Switchenko, Jean L. Koff, Rajni Sinha, Jonathan L. Kaufman, H. Jean Khoury, Nassoma Bumpers, et al. 2015. “A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma.” British Journal of Haematology 171 (4): 539–46. doi:10.1111/bjh.13637.